German pharmaceutical company Boehringer Ingelheim announced the initiation of the Phase I/II LENTICLAIR study for its gene therapy candidate BI 3720931 in cystic fibrosis (CF). The study is being conducted in collaboration with IP Group, the UK Respiratory Gene Therapy Consortium (GTC), and OXB.
Study Details
BI 3720931 is an inhaled lentiviral vector-based gene therapy designed to insert a functional copy of the CFTR gene into the DNA of airway epithelial cells. The therapy aims to improve lung function and reduce exacerbations for CF patients, regardless of their specific mutations. The study is expected to conclude in early 2027.
Cystic Fibrosis Background
CF is a hereditary, lifelong disease affecting over 100,000 people globally. Caused by mutations in the CFTR gene, it leads to the production of thick, sticky mucus that clogs the airways, causing severe respiratory issues. Current treatments with CFTR modulators have limitations, as they are not suitable for 10-15% of patients due to mutation type or intolerance.-Fineline Info & Tech
Leave a Reply